Literature DB >> 16917508

Envisioning future strategies for vaccination against tuberculosis.

Stefan H E Kaufmann1.   

Abstract

The design of tuberculosis vaccines has entered a new era. Although several new vaccine candidates will pass Phase I clinical trials within the next year, I believe that the most effective vaccination strategy will be to combine different vaccine candidates and to use a prime-boost approach. This strategy, however, would require several years of iterative vaccine trials, unless the process is expedited by the identification of reliable biomarkers for assessing vaccine efficacy. In this Essay, I briefly summarize past and present attempts to develop a vaccine against tuberculosis, and I describe, using imagined scenarios, the tuberculosis vaccination schemes that might become available from a large repertoire of candidate schemes in the near and distant future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917508     DOI: 10.1038/nri1920

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  40 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

Review 2.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

3.  Induction of an Antibody Response against Plasmodium falciparum F2RIIEBA by Heterologous Prime-boost Immunisation.

Authors:  Rapeah Suppian; Norazmi Mohd Nor
Journal:  Trop Life Sci Res       Date:  2013-08

4.  In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry.

Authors:  Meseret Habtamu; Markos Abebe; Abraham Aseffa; Anne Margarita Dyrhol-Riise; Anne Spurkland; Greger Abrahamsen
Journal:  J Immunol Methods       Date:  2018-07-04       Impact factor: 2.303

5.  Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity.

Authors:  Simone A Joosten; Krista E van Meijgaarden; Pascale C van Weeren; Fatima Kazi; Annemieke Geluk; Nigel D L Savage; Jan W Drijfhout; Darren R Flower; Willem A Hanekom; Michèl R Klein; Tom H M Ottenhoff
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

6.  Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages.

Authors:  Nadia L Ferrer; Ana B Gomez; Olivier Neyrolles; Brigitte Gicquel; Carlos Martin
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

7.  T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.

Authors:  Pascal Launois; Annie Drowart; Eliane Bourreau; Pierre Couppie; Claire-Michèle Farber; Jean-Paul Van Vooren; Kris Huygen
Journal:  Clin Dev Immunol       Date:  2010-09-27

8.  Secreted transcription factor controls Mycobacterium tuberculosis virulence.

Authors:  Sridharan Raghavan; Paolo Manzanillo; Kaman Chan; Cole Dovey; Jeffery S Cox
Journal:  Nature       Date:  2008-08-07       Impact factor: 49.962

9.  Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.

Authors:  D Neil Wedlock; Michel Denis; Gavin F Painter; Gary D Ainge; H Martin Vordermeier; R Glyn Hewinson; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

10.  Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.

Authors:  Kerstin Werninghaus; Anna Babiak; Olaf Gross; Christoph Hölscher; Harald Dietrich; Else Marie Agger; Jörg Mages; Attila Mocsai; Hanne Schoenen; Katrin Finger; Falk Nimmerjahn; Gordon D Brown; Carsten Kirschning; Antje Heit; Peter Andersen; Hermann Wagner; Jürgen Ruland; Roland Lang
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.